Genprex (GNPX) vs SciSparc (SPRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SciSparc is the larger company by market cap ($2.6 million vs $2.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNPX | SPRC |
|---|---|---|
| Share price | $2.75 | $4.43 |
| Market cap | $2.25M | $2.57M |
| 1-day change | +4.96% | -4.53% |
| P/E ratio (TTM) | — | 0.02 |
| EPS (TTM) | $-9.35 | $248.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1,210.00 | $43.65 |
| 52-week low | $2.53 | $2.98 |
| Distance from 52-week high | -99.77% | -89.85% |
| Average volume | 243.03K | 180.20K |
| Shares outstanding | 819.71K | 580.97K |
| Employees | 13 | 3 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Genprex
GNPX stock →Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Healthcare · Biotechnology · 13 employees
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Healthcare · Biotechnology · 3 employees
GNPX vs SPRC FAQ
Which is bigger, Genprex or SciSparc?
SciSparc (SPRC) is larger, with a market capitalization of $2.57M compared with $2.25M for Genprex (GNPX).
Are Genprex and SciSparc in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.